4 news items
Autolus Therapeutics Presents Additional Data Analysis Of Pivotal Phase 2 Felix Study Of obe-cel For Adult r/r B-all In An Oral Presentation At ASCO
AUTL
31 May 24
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
AUTL
31 May 24
The majority
Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views
AUTL
18 Mar 24
. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
AUTL
12 Mar 24
and found no major or critical observations in their summary report. "We are really proud of our brand-new facility
- Prev
- 1
- Next